Lombard Medical Ord (EVAR) 0.94 $EVAR Lombard Medical

New Post Public Reply Private Reply Replies (0) Message Board

Sep 21, 2016 at 5:11 AM

Lombard Medical Ord (EVAR) 0.94 $EVAR

Lombard Medical Reports 2016 Second Quarter, Six-Month Financial Results and Provides Update on Strategic Initiatives
GlobeNewswire - Mon Aug 22, 3:00PM CDT
Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAAs), today reported financial results, provided business highlights for the second quarter and six months ended June 30, 2016, and announced a significant operational restructuring and the exploration of strategic alternatives to enhance shareholder value.
EVAR: 0.94 (+0.08)

Lombard Medical Reschedules 2016 Second Quarter, Six-Month Financial Results Release and Conference Call Date to August 22 to Provide Complete Information on Operational Initiatives
GlobeNewswire - Fri Aug 12, 3:00PM CDT
Lombard Medical, Inc. (Nasdaq:EVAR), a medical device company focused on Endovascular Aortic Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that it has rescheduled the date to report its 2016 Second Quarter, Six-Month Financial Results to Monday, August 22, 2016, in order to provide complete information on operational initiatives that are underway, but will not be fully implemented until next week. In addition to details on those initiatives, management will discuss financial results and provide a business update on a conference call with the investment community at 4:30 p.m. Eastern Time on Monday, August 22, 2016. Note that as a foreign private issuer, Lombard is not subject to the quarterly reporting requirements of the Securities and Exchange Commission and as such, is not subject to SEC quarterly reporting timelines.
EVAR: 0.94 (+0.08)

Lombard Medical Announces 2016 Second Quarter, Six-Month Financial Results Release and Conference Call Date
GlobeNewswire - Mon Aug 08, 5:00AM CDT
Lombard Medical, Inc. (Nasdaq:EVAR), a medical device company focused on Endovascular Aortic Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that it will release its 2016 second quarter and six-month financial results after the market closes on Monday, August 15, 2016. In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m. Eastern Time on Monday, August 15, 2016, to discuss financial results and provide a business update.
EVAR: 0.94 (+0.08)

Lombard Medical Announces CE Mark Approval for IntelliFlex(TM) LP Delivery System for the Aorfix(TM) Abdominal Aortic Aneurysm Endovascular Stent Graft
GlobeNewswire - Mon Jun 20, 11:29AM CDT
Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that it has received CE Mark approval for its IntelliFlex(TM) Low Profile (LP) Delivery System for the Aorfix(TM) Endovascular Stent Graft. This new and innovative system will be used for the delivery of the Aorfix endovascular stent graft, the only AAA stent graft with global approval to treat aortic neck angulation up to 90 degrees. The Company plans to begin shipments in July to its direct markets in the UK and Germany, and expects a full commercial launch in the other European markets later in the year.
EVAR: 0.94 (+0.08)

Lombard Medical Reports Positive Five-Year Aorfix(TM) Endovascular Stent Graft Clinical Results in AAA Patients with Challenging Anatomy
GlobeNewswire - Mon Jun 13, 5:00AM CDT
Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced positive clinical results from The Prospective Aneurysm Trial: High Angle Aorfix(TM) Bifurcated Stent Graft (PYTHAGORAS trial) at the 2016 Society for Vascular Surgery Annual Meeting in National Harbor, Maryland. The PYTHAGORAS trial is a prospective, controlled, multicenter U.S. trial designed to evaluate the safety and effectiveness of the Aorfix endograft for the treatment of highly angulated aortic necks or tortuous aortoiliac anatomy.
EVAR: 0.94 (+0.08)

Lombard Medical Provides Update on Controlled Launch of the New Altura(R) Endovascular Stent Graft in Europe
GlobeNewswire - Wed Jun 08, 5:00AM CDT
Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced the following commercial update of the new Altura(R) Endovascular Stent Graft System.
EVAR: 0.94 (+0.08)

Lombard Medical to Present at the Jefferies 2016 Healthcare Conference
GlobeNewswire - Tue Jun 07, 1:05PM CDT
Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that CEO Simon Hubbert is scheduled to present at the Jefferies 2016 Healthcare Conference on Wednesday, June 8, 2016, at 4:00 pm ET in New York City.
EVAR: 0.94 (+0.08)

Lombard Medical Receives Australian Therapeutic Goods Administration (TGA) Approval for the Aorfix(TM) Endovascular Stent Graft for the Treatment of Abdominal Aortic Aneurysms
GlobeNewswire - Mon Jun 06, 5:00AM CDT
Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that the Australian Therapeutic Goods Administration (TGA) has approved the Aorfix(TM) Endovascular Stent Graft for inclusion on the Australian Register of Therapeutic Goods. The TGA has approved the use of Aorfix for the treatment of abdominal aortic aneurysms (AAAs) with aortic neck angulations up to 90 degrees.
EVAR: 0.94 (+0.08)

Lombard Medical Announces Scientific Presentation on Aorfix(TM) Endovascular Stent Graft Five-Year Clinical Data at the 2016 Society for Vascular Surgery Annual Meeting
GlobeNewswire - Thu Jun 02, 5:00AM CDT
Lombard Medical, Inc. (NASDAQ:EVAR), a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced that its Aorfix(TM) Endovascular Stent Graft will be featured in a scientific presentation at the 2016 Vascular Annual Meeting of the Society for Vascular Surgery (SVS) to be held at the Gaylord National Resort & Convention Center in National Harbor, Maryland, June 8-11, 2016. Aorfix is the first and only endovascular stent graft with global approvals for the treatment of patients with aortic neck angulations up to 90 degrees.
EVAR: 0.94 (+0.08)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...